HbA1c and fasting glucose measure blood sugar, whereas fasting insulin, HOMA-IR, and TG/HDL-C show how hard your pancreas is working to keep that sugar normal. In longitudinal cohorts (Whitehall II, n = 6,538; IRAS), lower insulin sensitivity (-34.2 HOMA2-%S points) and higher compensatory insulin secretion (+34% acute insulin response) appear 5 to 13 years before beta-cell decompensation drives blood sugar into diabetes. At the same time, HbA1c is skewed by red blood cell lifespan (38 to 60 days even in healthy adults, iron/B12 deficiency, hemolysis, or sickle cell trait [-0.29%]), and commercial insulin assays vary by 12% to 66% across labs (Rohlfing 2025). Fishtown Medicine pairs glycemic screening with same-platform fasting insulin (aiming for 3 to 6 uIU/mL while evaluating <3 uIU/mL for endurance adaptation vs RED-S under-fueling), HOMA-IR, and TG/HDL-C.
TL;DR: A normal HbA1c (< 5.7%) and fasting glucose (< 100 mg/dL) tell you that your blood sugar is still controlled today. They do not tell you how much extra insulin your pancreas is pumping to hold that line:
- Early physiological detection vs. late glycemic rise (Whitehall II & IRAS): In the Whitehall II cohort (Tabák et al., Lancet 2009, n = 6,538), adults who later developed type 2 diabetes already had 34.2 percentage points lower insulin sensitivity (HOMA2-%S) and higher compensatory insulin secretion (HOMA2-%B 85.0% vs 74.6%) 5 to 13 years before diagnosis. That long compensation was followed by a sharp 3-year beta-cell drop (HOMA2-%B down to 62.4%) as fasting glucose jumped from 104 to 133 mg/dL. In IRAS (Festa et al., Diabetes 2006), adults kept glucose normal over 5.2 years only by boosting acute insulin secretion +34% to offset a -35% drop in insulin sensitivity.
- Complementary physiology alongside standard screening (Hoorn, PROSPER, ADA 2023/2026): Because diabetes is defined by blood sugar, baseline fasting glucose (OR 9.0 in the Hoorn Study) and HbA1c (OR 3.8) remain stronger direct predictors of crossing the diabetes line than HOMA-IR (OR 2.8) or fasting insulin alone (OR 1.9). We add fasting insulin, HOMA-IR, and TG/HDL-C to catch compensated metabolic strain early, alongside standard glycemic and heart screening (ApoB, blood pressure, hs-CRP).
- Why our 3 to 6 uIU/mL insulin window is tracked on the same lab (Rohlfing 2025): Commercial lab reference ranges run up to 25 uIU/mL, while healthy non-obese cohorts average 5.1 to 5.8 uIU/mL. Because commercial insulin immunoassays vary by 12% to 66% across manufacturers (only 1 of 12 assays matched mass spectrometry in Rohlfing et al., CCLM 2025), we use 3 to 6 uIU/mL (6.1 to 9.0 borderline, 9.1+ high) as a clinical range tracked serially on the same lab platform.
- When HbA1c misleads (Cohen Blood 2008, Lacy JAMA 2017) and when low insulin (< 3 uIU/mL) warns of under-fueling (IOC REDs 2023): Mean red blood cell (RBC) age ranges from 38 to 60 days even in healthy adults, and iron/B12 deficiency, hemolysis, or sickle cell trait (-0.29% lower HbA1c) can skew HbA1c. Meanwhile, a fasting insulin below 3 uIU/mL requires clinical context to separate healthy endurance training sensitivity from low energy availability (RED-S, which cuts insulin by 34% to 38%) or failing beta-cell secretion.
Table of Contents
- What do fasting glucose, HbA1c, fasting insulin, HOMA-IR, and TG/HDL-C each measure?
- How many years before diabetes does insulin resistance begin?
- Does fasting insulin or HOMA-IR beat glucose and HbA1c at predicting diabetes or heart events?
- What is a healthy fasting insulin level, and why do lab assays vary?
- When does HbA1c give a false reading?
- What does a very low fasting insulin (under 3 uIU/mL) mean?
- Guidelines from the Clinic
- Actionable Steps for Metabolic Reset
- Common Questions
- Deep Questions
What do fasting glucose, HbA1c, fasting insulin, HOMA-IR, and TG/HDL-C each measure?
Fasting glucose (FPG) and HbA1c measure blood sugar concentration, whereas fasting insulin, HOMA-IR, and the triglyceride-to-HDL (TG/HDL-C) ratio measure the hormonal effort and lipid spillover behind that blood sugar.123
Many patients are told their metabolism is healthy because their HbA1c is under 5.7% and their fasting glucose is under 100 mg/dL (the American Diabetes Association prediabetes cutoffs).45 Those numbers matter, yet each test captures a different piece of physiology:
- Fasting Plasma Glucose (FPG) & HbA1c: Measure circulating glucose (FPG) and the percentage of hemoglobin coated with sugar over the life of your red blood cells (HbA1c). Normal blood sugar can coexist with significant insulin resistance as long as your pancreatic beta cells pump extra insulin to compensate.67 Conversely, weak beta-cell secretion can let blood sugar drift up without high insulin.7
- Fasting Insulin: Reflects three things at once: basal pancreatic insulin secretion, liver (hepatic) extraction (50% to 80% of portal insulin is cleared on first pass), and whole-body clearance.89 In a gold-standard hyperinsulinemic-euglycemic clamp study of obese men (ter Horst et al., Int J Obes 2015), fasting insulin detected peripheral insulin resistance with an AUC of ~0.80 compared to 0.55 for fasting glucose.10 Across broader cohorts (Otten et al., Diabetologia 2014 meta-analysis), fasting surrogates correlate moderately with clamp sensitivity (r ~ 0.60 to 0.65).1112
- HOMA-IR (HOMA1 vs HOMA2): Pairs fasting insulin and fasting glucose to model basal liver-pancreas feedback. Classic HOMA1-IR is calculated as (fasting insulin [uIU/mL] x fasting glucose [mg/dL]) / 405, whereas HOMA2-IR uses a non-linear computer model. The two scores are not numerically interchangeable (an upper 95th percentile of 2.68 on HOMA1-IR corresponds to 1.80 on HOMA2-IR in the same healthy cohort, Tohidi et al., Clin Biochem 2014).1314
- Triglyceride-to-HDL-C (TG/HDL-C) Ratio: Captures liver VLDL triglyceride export and CETP-driven HDL remodeling when liver insulin signaling is strained.1516 Two rules apply: (1) you must use mg/dL units (because mmol/L conversion factors differ between triglycerides and cholesterol), and (2) TG/HDL-C can underestimate insulin resistance in adults of African ancestry, where lipoprotein lipase activity often keeps triglycerides low despite insulin resistance (Kim-Dorner et al., Metabolism 2010).1517
How many years before diabetes does insulin resistance begin?
Compensated insulin resistance and hypersecretion are detectable 5 to 13 years before a type 2 diabetes diagnosis, with rapid beta-cell decompensation typically occurring in the final 3 to 5 years (moderate-to-high certainty).126
Three landmark prospective cohorts map how the pancreas compensates before blood sugar breaks through diagnostic cutoffs:
| Cohort & Study Design | Sample Size & Follow-Up | Physiological Trajectory & Effect Sizes | Key Clinical Nuance & Limitations |
|---|---|---|---|
| Whitehall II (Tabák et al., Lancet 2009) | 6,538 adults (505 incident T2D cases, 7.7%) over median 9.7 yrs (modeled 13 yrs back) | Years -13 to -5: Future cases already had -34.2 percentage points lower HOMA2-%S sensitivity and higher HOMA2-%B secretion (85.0% vs 74.6%). Years -4 to -3: HOMA2-%B rose to 92.6%. Final 3 years: HOMA2-%B fell to 62.4% as FPG jumped from 104 to 133 mg/dL (5.79 to 7.40 mmol/L).1 | Modeled FPG in future cases was already ~98 mg/dL at -13 yrs and 104 mg/dL at -3 yrs, so Whitehall II shows a decade-plus lag before diabetes diagnosis, not that every patient kept FPG < 100 and HbA1c < 5.7% for 13 years.11819 |
| IRAS (Festa et al., Diabetes 2006; Lorenzo et al., Diabetes Care 2010) | 826 multiethnic adults (128 incident T2D, 15.5%) over 5 to 5.2 yrs with repeat FSIGT | Participants who kept normal glucose tolerance over 5.2 years had a -35% drop in insulin sensitivity ($S_I$) that was offset by a +34% jump in acute insulin response (AIR). Each 1-SD higher $S_I$ (OR 0.50) and AIR (OR 0.51) cut 5-year diabetes risk in half.26 | Direct repeat intravenous testing proves that rising insulin secretion masks falling sensitivity until beta cells tire out.2620 |
| San Antonio Heart Study (Haffner et al., Diabetes 1992 & Diabetologia 1996/1997) | 1,276 Mexican-American (11.7% T2D) & non-Hispanic White (5.0% T2D) adults over 7 to 8 yrs | In adults starting with normal glucose tolerance, 17.6% (148/839) progressed to impaired glucose tolerance (IGT) over 7 years. High baseline fasting insulin and blunted 30-minute insulin response independently predicted conversion.212223 | Establishes a 7-to-8-year predictive signal across diverse ancestries, adjusted for body mass index.2122 |
Does fasting insulin or HOMA-IR beat glucose and HbA1c at predicting diabetes or heart events?
No - earlier physiological detection is not the same as superior standalone outcome prediction (moderate certainty for diabetes; low-to-moderate certainty for incremental heart risk).32425
Because clinical diabetes is defined by blood glucose and HbA1c thresholds, a patient whose fasting glucose (98 mg/dL) or HbA1c (5.6%) is already close to the diagnostic line is statistically nearer to crossing that line than someone with high insulin and a fasting glucose of 82 mg/dL:
- Incident Type 2 Diabetes (Hoorn, PROSPER, Panasonic Cohort):
- In the population-based Hoorn Study (Ruijgrok et al., Diabetologia 2018, n = 1,349, 11.3% incident T2D over 6.4 years), top-versus-bottom quintile adjusted odds ratios were 9.0 (95% CI 4.4 to 18.5) for FPG, 6.1 (2.9 to 12.7) for 2-hour post-load glucose, 3.8 (2.0 to 7.2) for HbA1c, 2.8 (1.4 to 5.6) for HOMA-IR, and 1.9 (0.9 to 3.6) for fasting insulin.3
- In older adults (70 to 82 years) in PROSPER (Welsh et al., Diabetologia 2014, n = 4,742, 6.0% incident T2D over 3.2 years), top-versus-bottom tertile HOMA-IR (HR 4.80, 95% CI 3.14 to 7.33) and fasting insulin (HR 2.43, 1.65 to 3.58) strongly predicted diabetes.26
- In the Panasonic Cohort Study 10 (Yuge et al., Cardiovasc Diabetol 2023, n = 120,613, 5.0% incident T2D over 6 years), TG/HDL-C independently predicted diabetes (HR 1.03 per unit after adjusting for FPG; 10-year AUC 0.679).17
- Cardiovascular Events (Gast Meta-Analysis, SAHS, Chen Meta-Analysis vs PROSPER):
- Across 65 studies (516,325 adults without diabetes, Gast et al., PLoS One 2012), each 1-SD rise in HOMA-IR was linked to a 46% higher coronary heart disease risk (RR 1.46, 95% CI 1.26 to 1.69), compared with RR 1.21 (1.13 to 1.30) for fasting glucose and RR 1.04 (0.96 to 1.12) for fasting insulin alone.24
- In the San Antonio Heart Study (Hanley et al., Diabetes Care 2002, n = 2,569, 7.3% CVD events over 8 years), top-quintile HOMA-IR carried an adjusted OR of 1.94 (1.05 to 3.59).27 Across 13 cohorts (207,515 adults, Chen et al., NMCD 2022), high TG/HDL-C carried HR 1.43 (1.26 to 1.62; 1.26 after publication-bias adjustment).28
- However, in older high-risk adults in PROSPER (Welsh et al., 2014) and in normoglycemic adults in a large Chinese cohort (Wang et al., Diabetes Care 2022), HOMA-IR did not add heart prediction (HR 0.94 and HR 1.03) once standard risk factors were included.2629
- What this means for your panel (ADA / AACC 2023 Guideline, Sacks et al.): Fasting insulin, HOMA-IR, and TG/HDL-C complement and never replace HbA1c, fasting glucose, ApoB, and blood pressure.2530 We use them to spot compensated insulin resistance early so you can adjust nutrition, muscle mass, and sleep before blood sugar ever rises.
What is a healthy fasting insulin level, and why do lab assays vary?
In healthy, lean, non-diabetic cohorts, median fasting insulin is 5.1 to 5.8 uIU/mL (well below commercial lab ceilings of 18 to 25 uIU/mL), which is why Fishtown Medicine uses 3 to 6 uIU/mL as our optimal preventive range while tracking results on the same lab platform (high certainty on inter-assay variability).133132
| Study / Cohort & Assay Platform | Sample & Reference Population | Fasting Insulin & HOMA-IR Distribution | Clinical Takeaway |
|---|---|---|---|
| Commercial Lab Interval (Xu et al., Anal Biochem 2020, ADVIA Centaur XP) | Routine clinical laboratory reference population | 3.0 to 25.0 uIU/mL (mIU/L) | Reflects an unselected population with high rates of overweight and silent insulin resistance.33 |
| D.E.S.I.R. Cohort (Gallois et al., Diabetes Metab 1996, Abbott EIA) | 3,081 non-diabetic reference adults (from n = 4,032) | Medians 5.1 to 5.6 uIU/mL (95th percentiles 11.2 to 12.6 uIU/mL) | Typical values in metabolically healthy adults cluster between 3 and 6 uIU/mL.31 |
| Tehran Lipid & Glucose Study (Tohidi et al., 2014 & Ghasemi et al., 2015, ECLIA) | 309 healthy non-obese adults (4,942 followed 9.2 yrs for T2D, 7.0% incidence) | Central 95% insulin: 2.11 to 12.49 uIU/mL. HOMA1-IR: 0.63 to 2.68 vs HOMA2-IR: 0.40 to 1.80. ROC T2D cutoffs: 9.16 (men) / 11.13 (women) | Shows why HOMA1 and HOMA2 cannot be mixed, and why risk rises sharply above ~9 uIU/mL.1334 |
| Healthy Reference Cohorts (Li et al., 2012; Matli et al., CCLM 2021) | 1,434 healthy men (Li); 1,065 stringent healthy adults (Matli) | Median insulin 5.79 uIU/mL (1.57 to 16.32); median HOMA-IR 1.09 (IQR 0.85 to 1.42, 97.5th 2.35) | Confirms that healthy HOMA-IR centers near ~1.0 (IQR < 1.5).3536 |
Why you should always compare fasting insulin on the same lab platform (Marcovina 2007; Rohlfing 2025)
Unlike HbA1c (which is standardized globally by the NGSP), commercial serum insulin immunoassays are not yet fully standardized:
- An American Diabetes Association (ADA) Workgroup (Marcovina et al., Clin Chem 2007) found between-laboratory coefficients of variation (CV) of 12% to 66% (median 24%) across commercial insulin assays.37
- In 2025, Rohlfing et al. (Clin Chem Lab Med 2025) compared 12 current insulin assays from 9 manufacturers against the gold-standard isotope-dilution mass spectrometry (IDMS) reference method: only 1 of 12 assays fully met agreement criteria, even though each individual lab platform had tight internal repeatability.32
- Our clinical rule: Our 3 to 6 uIU/mL optimal window (6.1 to 9.0 uIU/mL borderline high; 9.1+ uIU/mL high) is a preventive heuristic read alongside fasting glucose, HbA1c, TG/HDL-C, ALT/GGT, and waist circumference. We track your serial draws on the same laboratory platform (Quest or LabCorp) under standardized 10-to-12-hour morning fasting conditions.
When does HbA1c give a false reading?
Even when your lab test is accurate, variations in average red blood cell (RBC) age (38 to 60 days in healthy adults, Cohen et al., Blood 2008) or hemoglobin variants (-0.29% in sickle cell trait, Lacy et al., JAMA 2017) can push HbA1c falsely high or falsely low at the same blood sugar (high certainty).383940
In a biotin-labeling study (Cohen et al., Blood 2008), mean circulating RBC age ranged from 38 to 60 days even among healthy non-diabetic adults. That spread is wide enough to shift HbA1c across diagnostic cutoffs without any change in blood sugar.38
| Condition or Confounder | Effect on HbA1c at Identical Blood Sugar | Biological or Assay Mechanism & Clinical Action |
|---|---|---|
| Iron Deficiency & Iron-Deficiency Anemia (English et al., Diabetologia 2015; Cavagnolli 2015) | Falsely Higher HbA1c (moderate certainty) | Slower red cell turnover and altered glycation raise HbA1c into the "prediabetes" range (5.7% to 6.0%) despite normal glucose and insulin; recheck after iron repletion.414243 |
| Vitamin B12 or Folate Deficiency (Gram-Hansen 1990) | Often Higher HbA1c (low-moderate certainty) | Reduced red cell production increases average age of circulating cells; B12/folate treatment drops HbA1c as young reticulocytes enter blood.4144 |
| Splenectomy / Asplenia (O'Keeffe et al., JAMA 2016) | Often Higher HbA1c (context-dependent) | Slower clearance of aged red cells lengthens glycation exposure when underlying hemolysis is absent.45 |
| Hemolysis or Blood Loss (Kiniwa 2019; Saudek JAMA 2006) | Falsely Lower HbA1c (high certainty) | Shortened red cell survival cuts glycation time regardless of assay method, hiding high blood sugar.4647 |
| Sickle Cell Trait (HbAS) & Hemoglobin Variants (Lacy et al., JAMA 2017; Rohlfing 2016) | Falsely Lower (-0.29% in HbAS) or Method-Dependent (high certainty) | At the same fasting or 2-hour glucose, African American adults with sickle cell trait had 0.29 percentage points lower HbA1c (Lacy 2017).3940 |
| Advanced Chronic Kidney Disease (KDIGO 2022; Galindo 2020) | Often Lower / Bidirectional (high certainty that reliability drops) | Shortened RBC survival, erythropoietin (ESA), or iron infusions skew HbA1c downward.4849 |
When HbA1c and fasting glucose disagree, we follow ADA 2026 Standards of Care (Bajaj et al., Diabetes Care 2025): we check a CBC with MCV/reticulocytes, ferritin, B12/MMA, and use plasma glucose criteria, oral glucose tolerance testing (OGTT), fructosamine / glycated albumin, or a 2-week preventive CGM.449
What does a very low fasting insulin (under 3 uIU/mL) mean?
An isolated fasting insulin below 3 uIU/mL is not an automatic badge of health and cannot by itself diagnose RED-S; interpreting it requires pairing the number with your training load, calorie intake, blood sugar, and hormone panel (low certainty for any standalone cutoff; high clinical utility as a context gate).85051
At Fishtown Medicine, we keep our optimal fasting insulin as a 3 to 6 uIU/mL range because readings of 1 or 2 uIU/mL branch into three distinct physiological states:
| Clinical Context Accompanying < 3 uIU/mL | Underlying Physiology & Trial Evidence | Next Clinical Step at Fishtown Medicine |
|---|---|---|
| 1. Well-fueled endurance athlete with stable weight, normal glucose, and healthy hormones | High insulin sensitivity & hepatic clearance (King et al., J Appl Physiol 1987; Engdahl et al., 1995): Endurance-trained adults show higher clamp glucose disposal with smaller pulsatile insulin bursts.5253 | Reassurance (no need to raise insulin). If energy, menstrual cycles or testosterone, bone density, and blood sugar are healthy, a low fasting insulin is normal adaptation.5052 |
| 2. High training volume or calorie restriction with fatigue, missed periods, low libido/T, or bone stress injuries | Low Energy Availability / RED-S (Koehler et al., J Sports Sci 2016; IOC REDs Consensus 2023, Mountjoy & Stellingwerff BJSM 2023): Just 4 days of low energy availability cuts fasting insulin by 34% to 38% alongside leptin.505154 | Never prescribe fasting or restriction. Run the multidimensional IOC REDs CAT2 evaluation: thyroid (TSH, free T4, free T3), morning sex hormones (LH, FSH, estradiol or total/free T), ferritin, and a DEXA scan with Z-scores, and restore carbohydrate/protein fueling around workouts.505155 |
| 3. Prolonged fasting (36-60 hrs) OR rising fasting glucose (>= 100 mg/dL) / high HbA1c | Fasting glucose-sparing adaptation (Jørgensen 2021) OR Beta-Cell Secretory Failure (Stone et al., Diabetes Care 2024): Low insulin with high blood sugar means the pancreas is failing to secrete insulin (LADA, monogenic, or pancreatogenic diabetes), making a low HOMA-IR falsely reassuring.45657 | Repeat after standardized 10-to-12-hour overnight fasting (if drawn after prolonged fasting). If glucose or HbA1c is high alongside low insulin, order paired fasting C-peptide + glucose and islet autoantibodies (GAD65, IA-2, ZnT8).457 |
Guidelines from the Clinic
Actionable Steps for Metabolic Reset
Move beyond a single 90-day average:
- Add Fasting Insulin, HOMA-IR, and TG/HDL-C (mg/dL) on the Same Lab Platform: Ask for a 10-to-12-hour morning fasting draw on a consistent lab (Quest or LabCorp) alongside fasting glucose and HbA1c so assay differences (12% to 66% across manufacturers) never cloud your trend.
- Audit HbA1c Discordance Against Your Red Blood Cells: If your HbA1c is 5.6% to 5.9% while your fasting insulin (3 to 5 uIU/mL) and fasting glucose (82 mg/dL) are ideal, check ferritin, B12/folate, MCV, or a 2-week preventive CGM before accepting a prediabetes label.
- Build Your Largest Glucose Sink (Skeletal Muscle): Progressive resistance training 2 to 4 days per week plus Zone 2 aerobic work increases muscle GLUT4 glucose disposal without requiring extra pancreatic insulin.
- Anchor Meals with Protein (30-40g) and Walk 10 Minutes After Eating: Eating protein and fiber first and taking a 10-minute post-meal walk blunts post-meal glucose excursions and reduces cumulative beta-cell secretory demand.
- Respect the < 3 uIU/mL Floor in Active Men and Women: If your fasting insulin is 1 or 2 uIU/mL and you feel fatigued, cold, injured, or hormonally flat, fuel with carbohydrates and protein around training instead of fasting.
Related at Fishtown Medicine
- 9-System Biomarker Reference Guide: Optimal vs Standard Lab Ranges - complete reference for fasting insulin, HOMA-IR, TG/HDL, ApoB, liver enzymes, and all 9 systems
- How to Read Your Lab Results - why reference intervals hide early metabolic drift and how to read your trend
- Understanding Insulin Resistance - how muscle and liver insulin signaling work
- Insulin Resistance at a Normal Weight - why body mass index misses lean visceral insulin resistance
- Preventive CGM Guide - using 2-to-4-week continuous glucose monitoring to map personal food and sleep responses
- ApoB & Heart Health - why insulin resistance creates discordance between normal LDL-C and high ApoB particle number
- High Ferritin: From Iron Overload to Inflammation - why 90% of high ferritin is metabolic (MASLD / DIOS)
- Autoimmune Gastritis & Low Ferritin - how iron deficiency falsely raises HbA1c
- Body Composition Testing (DEXA) - quantifying visceral fat (VAT), skeletal muscle (ALMI), and bone Z-scores in RED-S
Scientific References
- Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. "Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study." The Lancet. 2009;373(9682):2215-2221. PubMed
- Lorenzo C, Wagenknecht LE, D'Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM. "Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study." Diabetes Care. 2010;33(1):67-72. PubMed
- Ruijgrok C, Dekker JM, Beulens JW, et al. "Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study." Diabetologia. 2018;61(1):93-100. DOI
- Bajaj M, McCoy RG, Balapattabi K, et al.; American Diabetes Association Professional Practice Committee. "2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes - 2026." Diabetes Care. 2026;49(Suppl 1):S27-S49. DOI
- Kalyani RR, Neumiller JJ, Maruthur NM, Wexler DJ. "Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review." JAMA. 2025. DOI
- Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. "The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study." Diabetes. 2006;55(4):1114-1120. PubMed
- Esser N, Utzschneider KM, Kahn SE. "Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia." Diabetologia. 2020;63(10):2007-2021. DOI
- Goodarzi MO, Cui J, Chen YD, Hsueh WA, Guo X, Rotter JI. "Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance." American Journal of Physiology-Endocrinology and Metabolism. 2011;301(2):E402-E408. PubMed
- Kim SH, Reaven GM. "Insulin clearance: an underappreciated modulator of plasma insulin concentration." Journal of Investigative Medicine. 2016;64(7):1162-1165. DOI
- ter Horst KW, Gilijamse PW, Koopman KE, et al. "Insulin resistance in obesity can be reliably identified from fasting plasma insulin." International Journal of Obesity. 2015;39(12):1703-1709. DOI
- Otten J, Ahrén B, Olsson T. "Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis." Diabetologia. 2014;57(9):1781-1788. DOI
- Abbasi F, Okeke Q, Reaven GM. "Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR)." Acta Diabetologica. 2014;51(2):193-197. PubMed
- Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. "Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study." Clinical Biochemistry. 2014;47(6):432-438. PubMed
- Haffner SM, Miettinen H, Stern MP. "The homeostasis model in the San Antonio Heart Study." Diabetes Care. 1997;20(7):1087-1092. PubMed
- Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M. "Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?" Metabolism. 2010;59(2):299-304. PubMed
- Yang Y, Wang B, Yuan H, Li X. "Triglycerides to High-Density Lipoprotein Cholesterol Ratio Is the Best Surrogate Marker for Insulin Resistance in Nonobese Middle-Aged and Elderly Population: A Cross-Sectional Study." International Journal of Endocrinology. 2021;2021:6676569. DOI
- Yuge H, Okada H, Hamaguchi M, et al. "Triglycerides/HDL cholesterol ratio and type 2 diabetes incidence: Panasonic Cohort Study 10." Cardiovascular Diabetology. 2023;22(1):308. DOI
- Færch K, Witte DR, Tabák AG, et al. "Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study." The Lancet Diabetes & Endocrinology. 2013;1(1):43-51. PubMed
- Hulman A, Simmons RK, Brunner EJ, et al. "Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study." Diabetologia. 2017;60(7):1252-1260. DOI
- Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ. "Longitudinal decline of beta-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study." The Journal of Clinical Endocrinology & Metabolism. 2013;98(10):4152-4159. PubMed
- Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. "Prospective analysis of the insulin-resistance syndrome (syndrome X)." Diabetes. 1992;41(6):715-722. PubMed
- Haffner SM, Miettinen H, Stern MP. "Are risk factors for conversion to NIDDM similar in high and low risk populations?" Diabetologia. 1997;40(1):62-69. PubMed
- Haffner SM, Miettinen H, Gaskill SP, Stern MP. "Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance." Diabetologia. 1996;39(10):1201-1207. PubMed
- Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. "Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis." PLoS One. 2012;7(12):e52036. PubMed
- Sacks DB, Arnold M, Bakris GL, et al. "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus." Diabetes Care. 2023;46(10):e151-e199. PubMed
- Welsh P, Preiss D, Lloyd SM, et al. "Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up." Diabetologia. 2014;57(12):2513-2523. DOI
- Hanley AJ, Williams K, Stern MP, Haffner SM. "Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study." Diabetes Care. 2002;25(7):1177-1184. PubMed
- Chen Y, Chang Z, Liu Y, et al. "Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population: A systematic review and meta-analysis of cohort studies." Nutrition, Metabolism and Cardiovascular Diseases. 2022;32(2):318-329. PubMed
- Wang T, Li M, Zeng T, et al. "Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study." Diabetes Care. 2022;45(8):1863-1872. PMC
- Arnett DK, Blumenthal RS, Albert MA, et al. "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease." Journal of the American College of Cardiology. 2019;74(10):e177-e232. PMC
- Gallois Y, Vol S, Cacès E, Balkau B; D.E.S.I.R. Study Group. "Distribution of fasting serum insulin measured by enzyme immunoassay in an unselected population of 4,032 individuals. Reference values according to age and sex." Diabetes & Metabolism. 1996;22(6):427-431. PubMed
- Rohlfing C, Petroski G, Hatten-Beck M, et al. "The current status of serum insulin measurements and the need for standardization." Clinical Chemistry and Laboratory Medicine. 2025. PubMed
- Xu YY, Xu SM, Li XM, et al. "Validation of the ADVIA Centaur XP system for the determination of insulin and its application." Analytical Biochemistry. 2020;592:113582. PubMed
- Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. "Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study." Acta Diabetologica. 2015;52(5):905-915. PubMed
- Li S, Huang S, Mo ZN, et al. "Generating a reference interval for fasting serum insulin in healthy nondiabetic adult Chinese men." Singapore Medical Journal. 2012;53(12):821-825. PubMed
- Matli B, Schulz A, Koeck T, et al. "Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals." Clinical Chemistry and Laboratory Medicine. 2021;59(11):1844-1851. PubMed
- Marcovina S, Bowsher RR, Miller WG, et al. "Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup." Clinical Chemistry. 2007;53(4):711-716. PubMed
- Cohen RM, Franco RS, Khera PK, et al. "Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c." Blood. 2008;112(10):4284-4291. PubMed
- Rohlfing C, Hanson S, Weykamp C, et al. "Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods." Clinica Chimica Acta. 2016;455:80-83. PubMed
- Lacy ME, Wellenius GA, Sumner AE, et al. "Association of Sickle Cell Trait With Hemoglobin A1c in African Americans." JAMA. 2017;317(5):507-515. DOI
- English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. "The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review." Diabetologia. 2015;58(7):1409-1421. DOI
- Cavagnolli G, Pimentel AL, Freitas PA, Gross JL, Camargo JL. "Factors affecting A1C in non-diabetic individuals: Review and meta-analysis." Clinica Chimica Acta. 2015;445:107-114. PubMed
- Guo W, Zhou Q, Jia Y, Xu J. "Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review." Medical Science Monitor. 2019;25:8371-8378. PubMed
- Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L. "Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency." Journal of Internal Medicine. 1990;227(2):133-136. PubMed
- O'Keeffe DT, Maraka S, Rizza RA. "HbA1c in the Evaluation of Diabetes Mellitus." JAMA. 2016;315(6):605-606. DOI
- Kiniwa N, Okumiya T, Tokuhiro S, et al. "Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level." Scandinavian Journal of Clinical and Laboratory Investigation. 2019;79(6):377-380. PubMed
- Saudek CD, Derr RL, Kalyani RR. "Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c." JAMA. 2006;295(14):1688-1697. DOI
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. "KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease." Kidney International. 2022;102(5S):S1-S127. DOI
- Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. "Glycemic Monitoring and Management in Advanced Chronic Kidney Disease." Endocrine Reviews. 2020;41(5):756-774. PubMed
- Stellingwerff T, Mountjoy M, McCluskey WT, et al. "Review of the scientific rationale, development and validation of the International Olympic Committee Relative Energy Deficiency in Sport Clinical Assessment Tool: V.2 (IOC REDs CAT2)." British Journal of Sports Medicine. 2023;57(17):1109-1118. PubMed
- Mountjoy M, Ackerman KE, Bailey DM, et al. "2023 International Olympic Committee's (IOC) consensus statement on Relative Energy Deficiency in Sport (REDs)." British Journal of Sports Medicine. 2023;57(17):1073-1097. PubMed
- Engdahl JH, Veldhuis JD, Farrell PA. "Altered pulsatile insulin secretion associated with endurance training." Journal of Applied Physiology. 1995;79(6):1977-1985. PubMed
- King DS, Dalsky GP, Staten MA, Clutter WE, Van Houten DR, Holloszy JO. "Insulin action and secretion in endurance-trained and untrained humans." Journal of Applied Physiology. 1987;63(6):2247-2252. PubMed
- Koehler K, Hoerner NR, Gibbs JC, Zinner C, Braun H, De Souza MJ, Schaenzer W. "Low energy availability in exercising men is associated with reduced leptin and insulin but not with changes in other metabolic hormones." Journal of Sports Sciences. 2016;34(20):1921-1929. PubMed
- Angelidi AM, Stefanakis K, Chou SH, Valenzuela-Vallejo L, Dipla K, Boutari C, Ntanasis-Stathopoulos I, Kokkoris P, Mantzoros CS. "Relative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments." Endocrine Reviews. 2024;45(5):676-708. PubMed
- Jørgensen SW, Hjort L, Gillberg L, et al. "Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males." American Journal of Physiology-Endocrinology and Metabolism. 2021;320(2):E281-E290. PubMed
- Stone SI, Balasubramanyam A, Posey JE. "Atypical Diabetes: What Have We Learned and What Does the Future Hold?" Diabetes Care. 2024;47(5):770-781. PMC
- Bojsen-Møller KN, Lundsgaard AM, Madsbad S, Kiens B, Holst JJ. "Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations-Role of Carbohydrate and Energy Availability." Diabetes. 2018;67(11):2129-2136. PubMed
Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.




